Data for Rivaroxaban to be presented at the ESC Congress 2010

August 28 - September 1, 2010
Stockholm, Sweden

Findings from the Phase III EINSTEIN-DVT study with Rivaroxaban have been presented during the Hot Line Session at the Annual Meeting of the European Society of Cardiology (ESC) in Stockholm, Sweden on August 31, 2010, 11:00-12:30 CEST.

On this occasion we have held a conference call for investors and analysts.

Tuesday, August 31, 2010:
Investor Conference Call on Rivaroxaban

with

Dr. Kemal Malik, Head of Global Development Bayer Schering Pharma
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

Background Information
About Xarelto® (rivaroxaban)Download PDF collect (412 KB)
About the Rivaroxaban Clinical Trial ProgramDownload PDF collect (822 KB)
About the EINSTEIN Clinical Trial ProgramDownload PDF collect (404 KB)
About the EINSTEIN-DVT StudyDownload PDF collect (350 KB)
About the RECORD Clinical Trial ProgramDownload PDF collect (381 KB)
About the ROCKET AF StudyDownload PDF collect (350 KB)
About the ATLAS ACS Clinical Trial ProgramDownload PDF collect (408 KB)
About the MAGELLAN StudyDownload PDF collect (410 KB)
Rivaroxaban BibliographyDownload PDF collect (455 KB)
About Deep Vein Thrombosis (DVT)Download PDF collect (333 KB)
About Venous Thromboembolism (VTE)Download PDF collect (512 KB)
About Acute Coronary Syndrome (ACS)Download PDF collect (408 KB)
About Stroke Prevention in Atrial FibrillationDownload PDF collect (388 KB)
About the History of AnticoagulantsDownload PDF collect (400 KB)
Glossary of TermsDownload PDF collect (373 KB)



Services